Trial Profile

A Multiple Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Risperidone Extended Release Capsules in Subjects With Schizophrenia, Schizoaffective Disorder

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 10 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Risperidone (Primary) ; Risperidone
Indications Schizophrenia
Focus Adverse reactions; Pharmacokinetics; Proof of concept
Sponsors Lyndra

Most Recent Events

18 Apr 2021 Results published in the Media Release
18 Apr 2021 According to a Lyndra Therapeutics media release, data from this study will be presented at the 2021 Congress of the Schizophrenia International Research Society (SIRS), on 18 Apr 2021.
23 Sep 2020 Status changed from planning to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com